EUVIMEDEUVIMED entdecken
Crossref

Comparison of Mefenamic Acid Plus Zinc Sulfate Versus Mefenamic Acid Alone in the Treatment of Primary Dysmenorrhea

Sadaf Zafar, Sibgha Anam

Journal of Pharma and Biomedics · 12.11.2026 · 4 (4) · 709-712

DOI: 10.56810/jpbm.004.04.0334 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharma and Biomedics, online erschienen am 12.11.2026. Verfasst von Sadaf Zafar und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary dysmenorrhea causes recurrent menstrual pain and may interfere with daily activities. Zinc has been studied as an additional treatment because of its possible effects on prostaglandin production and inflammatory pathways. This study compared mefenamic acid plus zinc sulfate with mefenamic acid alone in women with primary dysmenorrhea. A study reported as randomized was conducted at Lahore General Hospital, Lahore, from January to July 2022. Sixty-eight women aged 16–25 years were included, with 34 in each group. Group A received zinc sulfate 50 mg once daily plus mefenamic acid 250 mg three times daily, whereas Group B received mefenamic acid at the same dose without zinc. Treatment was administered around menstruation, and symptoms were assessed after three months using the Working ability, Location, Intensity, Days of pain and Dysmenorrhea (WaLIDD) scale. Mean WaLIDD scores decreased from 7.65 ± 1.37 to 3.00 ± 2.52 in Group A and from 6.82 ± 1.19 to 3.41 ± 2.12 in Group B. The reported within-group changes were statistically significant (p < 0.001). The post-treatment mean difference was −0.41 points (95% confidence interval [CI], −1.54 to 0.72; approximate p = 0.47, calculated from the group summaries). Although the reduction was numerically greater with zinc supplementation, the available results did not demonstrate a statistically significant difference between treatments at follow-up. Participant-level data are needed to compare changes from baseline reliably.

Zitieren

APA

Zafar, S., & Anam, S. (2026). Comparison of Mefenamic Acid Plus Zinc Sulfate Versus Mefenamic Acid Alone in the Treatment of Primary Dysmenorrhea. Journal of Pharma and Biomedics, 4(4), 709-712. https://doi.org/10.56810/jpbm.004.04.0334

Vancouver

Zafar S, Anam S. Comparison of Mefenamic Acid Plus Zinc Sulfate Versus Mefenamic Acid Alone in the Treatment of Primary Dysmenorrhea. Journal of Pharma and Biomedics. 2026;4(4):709-712. doi:10.56810/jpbm.004.04.0334

BibTeX
@article{Zafar2026,
  author = {Zafar, Sadaf and Anam, Sibgha},
  title = {Comparison of Mefenamic Acid Plus Zinc Sulfate Versus Mefenamic Acid Alone in the Treatment of Primary Dysmenorrhea},
  journal = {Journal of Pharma and Biomedics},
  year = {2026},
  volume = {4},
  number = {4},
  pages = {709--712},
  doi = {10.56810/jpbm.004.04.0334}
}
Kostenlos starten →